Prognostic Impact of Copy Number Alterations’ Profile and AID/RAG Signatures in Acute Lymphoblastic Leukemia (ALL) with BCR::ABL and without Recurrent Genetic Aberrations (NEG ALL) Treated with Intensive Chemotherapy

• Published in: Cancers Vol. 15; no. 22; p. 5431
• Main Authors: Libura, Marta, Karabin, Karolina, Tyrna, Paweł, Czyż, Anna, Makuch-Łasica, Hanna, Jaźwiec, Bożena, Paluszewska, Monika, Piątkowska-Jakubas, Beata, Zawada, Magdalena, Gniot, Michał, Trubicka, Joanna, Szymańska, Magdalena, Borg, Katarzyna, Więsik, Marta, Czekalska, Sylwia, Florek, Izabela, Król, Maria, Paszkowska-Kowalewska, Małgorzata, Gil, Lidia, Kapelko-Słowik, Katarzyna, Patkowska, Elżbieta, Tomaszewska, Agnieszka, Mądry, Krzysztof, Machowicz, Rafał, Czerw, Tomasz, Piekarska, Agnieszka, Dutka, Magdalena, Kopińska, Anna, Helbig, Grzegorz, Gromek, Tomasz, Lewandowski, Krzysztof, Zacharczuk, Marta, Pastwińska, Anna, Wróbel, Tomasz, Haus, Olga, Basak, Grzegorz, Hołowiecki, Jerzy, Juszczyński, Przemysław, Lech-Marańda, Ewa, Giebel, Sebastian, Jędrzejczak, Wiesław Wiktor
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 15.11.2023
• Subjects: Acute lymphoblastic leukemia; BCR protein; Chemotherapy; Copy number; Enzymes; Gene expression; Genetic engineering; Genetic markers; Health risk assessment; Immunoglobulins; Leukemia; Lymphatic leukemia; Medical prognosis; Mutation; Pediatrics; Polymerase chain reaction; Remission (Medicine)
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15225431

Adult acute lymphoblastic leukemia (ALL) is associated with poor outcomes. ALL is initiated by primary aberrations, but secondary genetic lesions are necessary for overt ALL. In this study, we reassessed the value of primary and secondary aberrations in intensively treated ALL patients in relation to mutator enzyme expression. RT-PCR, genomic PCR, and sequencing were applied to evaluate primary aberrations, while qPCR was used to measure the expression of RAG and AID mutator enzymes in 166 adult ALL patients. Secondary copy number alterations (CNA) were studied in 94 cases by MLPA assay. Primary aberrations alone stratified 30% of the patients (27% high-risk, 3% low-risk cases). The remaining 70% intermediate-risk patients included BCR::ABL1pos subgroup and ALL lacking identified genetic markers (NEG ALL). We identified three CNA profiles: high-risk bad-CNA (CNAhigh/IKZF1pos), low-risk good-CNA (all other CNAs), and intermediate-risk CNAneg. Furthermore, based on RAG/AID expression, we report possible mechanisms underlying the CNA profiles associated with poor outcome: AID stratified outcome in CNAneg, which accompanied most likely a particular profile of single nucleotide variations, while RAG in CNApos increased the odds for CNAhigh/IKZF1pos development. Finally, we integrated primary genetic aberrations with CNA to propose a revised risk stratification code, which allowed us to stratify 75% of BCR::ABL1pos and NEG patients.